Logotype for Konica Minolta Inc

Konica Minolta (4902) Q2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Konica Minolta Inc

Q2 2025 earnings summary

13 Jun, 2025

Executive summary

  • Revenue for the first half rose 5.6% year-over-year to ¥583.7 billion, driven by growth across all regions and segments, aided by yen depreciation and strong office and professional print segments.

  • Business contribution profit surged to ¥17.8 billion (up 679.4% YoY), but an operating loss of ¥0.7 billion was recorded due to ¥16.4 billion in global structural reform expenses and costs related to ending production at a Chinese subsidiary.

  • Net loss attributable to owners widened to ¥10.7 billion, impacted by foreign exchange losses and high tax expenses, with basic EPS at -¥21.66.

  • Precision Medicine Business is being divested, with Ambry Genetics to be sold for $600 million, and the segment to be classified as discontinued from Q3 FY2024.

  • Progress in global structural reform and business selection ahead of schedule, including ending production at a Wuxi subsidiary and transferring Ambry Genetics.

Financial highlights

  • FY24 6M revenue rose 5.6% year-over-year to ¥583.7 billion; gross profit up 9.9% to ¥260.6 billion.

  • Business contribution profit surged to ¥17.8 billion (up ¥15.5 billion YoY); free cash flow improved to ¥16.7 billion.

  • Net loss attributable to owners widened to ¥10.7 billion, impacted by foreign exchange losses and high tax expenses.

  • Gross profit ratio improved to 44.7% (up 1.7pt YoY); business contribution profit ratio at 3.1% (up 2.6pt YoY).

  • Operating profit impacted by ¥16.4 billion in structural reform expenses.

Outlook and guidance

  • FY24 revenue forecast revised down to ¥1,134.0 billion (from ¥1,160.0 billion); business contribution profit forecast at ¥42.0 billion.

  • Operating profit forecast revised to -¥14.0 billion, reflecting impairment risks and restructuring costs.

  • Net profit guidance unchanged, incorporating a ¥41.0 billion gain from Ambry Genetics share transfer.

  • Dividend forecast remains at zero for FY24, with resumption targeted for FY25 as profit recovers.

  • Profit attributable to owners and basic EPS forecasted at zero, reflecting the impact of discontinued operations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more